NASDAQ$CRSP
CRISPR Therapeutics AG · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Reported a net loss due to increased operating expenses and decreased collaboration revenue.
CRISPR Therapeutics reported positive top-line results from its Phase 1 CARBON trial of CTX110, received FDA designations for CTX001 and CTX120, and began treating patients in CTX130 trials. The company's cash position increased due to a public offering, but collaboration revenue decreased significantly, leading to a net loss for the quarter.
- Reported positive top-line results from the Phase 1 CARBON trial of CTX110 for B-cell malignancies.
- Received Rare Pediatric Disease designation from the FDA for CTX001 for sickle cell disease and transfusion-dependent beta thalassemia.
- Received Orphan Drug Designation (ODD) for CTX120 for relapsed or refractory multiple myeloma.
- Began treating patients in Phase 1 clinical trials of CTX130 for solid tumors and hematologic malignancies.
Headline financials
Revenue & EPS history
CRISPR Therapeutics · Revenue · Quarterly
$148K
Revenue by segment
CRISPR Therapeutics · $762K total across 1 segment · Q1 2022
- Grant Revenue$762K+126.1%100.0%
Forward guidance
CRISPR Therapeutics expects to report additional data from the CTX001 program later this year and initial data for the CTX120 and CTX130 programs next year. They also plan to initiate a Phase 1/2 trial of their allogeneic stem cell-derived therapy for Type 1 diabetes in 2021.
Tailwinds
- Reporting additional data from CTX001 program later this year.
- Reporting initial data for CTX120 and CTX130 programs next year.
- Initiating Phase 1/2 trial of allogeneic stem cell-derived therapy for Type 1 diabetes in 2021.
- Advancing clinical trials in hemoglobinopathies rapidly.
- Continuing enrollment in CTX120 and CTX130 trials.
Headwinds
- Potential delays in regulatory review due to the coronavirus pandemic.
- Manufacturing and supply chain interruptions.
- Adverse effects on healthcare systems.
- Disruption of the global economy.
- Uncertainties regarding intellectual property protection.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+2.1%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+1.4%
Avg return
30 days after
48%
19 / 40 earnings
Positive
+22.8%
Q3 2019
Best reaction
-7.7%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.1% | +2.4% | +6.3% | |
| Q4 2025 | +1.2% | +10.0% | +0.9% | |
| Q3 2025 | -1.0% | -4.7% | +4.5% | |
| Q1 2025 | -0.1% | -3.2% | +7.2% | |
| Q4 2024 | -2.8% | -8.3% | -18.2% | |
| Q3 2024 | +0.3% | +2.0% | -2.1% | |
| Q2 2024 | -3.5% | -8.0% | -11.9% | |
| Q1 2024 | -3.6% | +0.2% | +4.2% | |
| Q4 2023 | +9.5% | +9.3% | -9.0% | |
| Q3 2023 | +14.9% | +4.3% | +39.5% | |
| Q2 2023 | +4.1% | -2.6% | +0.3% | |
| Q1 2023 | +13.7% | +14.5% | +12.5% | |
| Q4 2022 | -1.0% | -5.6% | -15.2% | |
| Q3 2022 | +4.5% | -2.2% | +3.8% | |
| Q2 2022 | -7.7% | -3.4% | -20.1% | |
| Q1 2022 | -1.5% | +8.8% | +53.8% | |
| Q4 2021 | +5.7% | -0.5% | +15.1% | |
| Q3 2021 | -3.0% | -1.8% | -26.9% | |
| Q2 2021 | +1.1% | +1.4% | +3.4% | |
| Q1 2021 | -0.1% | -3.3% | -12.8% | |
| Q4 2020 | -6.8% | -7.5% | -23.3% | |
| Q3 2020 | -1.8% | -12.2% | +23.9% | |
| Q2 2020 | -4.4% | -5.4% | -1.6% | |
| Q1 2020 | -5.5% | -11.9% | +13.3% | |
| Q4 2019 | +2.0% | -2.1% | -34.0% | |
| Q3 2019 | +22.8% | +27.7% | +70.9% | |
| Q2 2019 | -2.3% | -3.9% | -11.2% | |
| Q1 2019 | -2.0% | -1.1% | -10.1% | |
| Q4 2018 | +14.3% | +26.2% | +8.0% | |
| Q3 2018 | +7.5% | +3.2% | +0.0% | |
| Q2 2018 | -2.7% | -2.7% | +3.0% | |
| Q1 2018 | -0.4% | +2.0% | +29.6% | |
| Q4 2017 | +10.2% | +9.7% | -16.0% | |
| Q3 2017 | -6.5% | -2.1% | +4.1% | |
| Q2 2016 | +9.4% | +10.1% | +6.7% | |
| Q2 2017 | +9.4% | +10.1% | +6.7% | |
| Q1 2016 | -0.1% | -2.9% | -14.2% | |
| Q1 2017 | +4.3% | -4.2% | -17.9% | |
| Q4 2016 | +11.1% | +13.3% | -12.4% | |
| Q3 2016 | -7.0% | -1.9% | -3.3% | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro